How to Buy Erasca Stock
Erasca Inc
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway.
Erasca stock last closed at $15.08, up 10.31% from the previous day, and has increased 984.89% in one year. It has overperformed other stocks in the Biotechnology industry by 10.54 percentage points. Erasca stock is currently +1,146.28% from its 52-week low of $1.21, and -37.89% from its 52-week high of $24.28.
As of Jun 22, 2026, there are 310.98M ERAS shares outstanding. The market cap of ERAS is $4.69B. In the last 24 hours, 8.99M ERAS shares were traded.
How to Buy Erasca Stock
Not sure how to invest in Erasca stock? Here's how.
- Figure out where to buy Erasca stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you choose where to buy Erasca stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Fund your brokerage account: Pick your method of payment and add your details.
- Evaluate Erasca stock: The Erasca ticker symbol is ERAS. Is Erasca stock a good investment? Should you buy shares of ERAS? How do ERAS's underlying business fundamentals look? Do top analysts think Erasca is a good buy? Why has ERAS's stock price moved recently? (Hint: Our stock market research tools can help you evaluate if ERAS is a good stock to buy).
- Make your ERAS buy order: Decide if you will purchase ERAS shares at the current market price or use a limit order to buy ERAS shares at a specific price.
- Keep an eye on your ERAS investment: Create a watchlist to key updates about your investment in Erasca stock.
Step 1: Figure out where to buy Erasca stock
You will need an online brokerage account in order to access the NASDAQ market and buy ERAS stock.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global financial markets: From Tech to Utilities, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal information so you can invest in ERAS stock today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to create a new brokerage account.
- Submit your info by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've filled out your info on the best stock app, your next step is to transfer the money for your investment:
Check out the video below to see the process of depositing funds into your new brokerage account.
Step 4: Evaluate Erasca stock
After you have figured out the best place to buy Erasca stock, it's very important to evaluate their stock prior to buying, so you actually wrap your head around the risk as well as the upside.
Erasca stock quick numbers
ERAS Due Diligence Checks
WallStreetZen was created to help average investors do more accurate fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on ERAS's stock page.
How is ERAS stock valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge ERAS's fair value.
Using relative valuations measures:
- ERAS may be overvalued based on its P/B ratio of 11.92x, relative to Biotechnology industry P/B ratio of 5.1x
You can do additional valuation analysis on ERAS's stock here.
ERAS Financial Summary
Positive Health Checks:
- There are more short-term assets than long-term liabilities on the ERAS balance sheet.
- There are more short-term assets than short-term liabilities on the ERAS balance sheet.
- ERAS has a low debt to equity ratio of 0.17.
- Total ERAS debt is lower than 5 years ago, relative to shareholder equity.
- ERAS has $244.20M in cash and short term investments. This is sufficient to cover its annual cash burn of $91.36M.
- ERAS has cash burn of 91364000. It has sufficient cash and short-term investments to cover this for at least one year.
Is Erasca stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 8 sell side analysts who give forecasts on ERAS, the consensus analyst rating on ERAS is a Strong Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Latest ERAS Analyst Ratings
Kelsey Goodwin, a top 7% analyst from Piper Sandler maintains ERAS with a strong buy rating and raises their ERAS price target from $11.00 to $18.00, on Mar 13, 2026.
Piper Sandler's Kelsey Goodwin raised their price target on Erasca (NASDAQ: ERAS) by 63.6% from $11 to $18 on 2026/03/13. The analyst maintained their Strong Buy rating on the stock.
Erasca reported its Q4 and FY 2025 earnings.
According to Goodwin, the print highlighted the fact that the ERAS-0015 update in 1H 2026 will incorporate data from both the U.S. and China.
The analyst said they continue to think Erasca possesses a pan-RAS inhibitor that could be best-in-class, differentiating it from daraxonrasib and tackling the sizable market for RAS-mutant cancers.
Earnings Report
Erasca reported:
For Q4 2025:
- Loss per share of $0.10, compared to Q4 2024’s loss of $0.11.
For FY 2025:
- Loss per share of $0.44, compared to FY 2024’s loss of $0.69.
Management did not provide EPS and revenue guidance in its press release.
Chairman, Co-founder, & CEO Jonathan E. Lim, M.D. commented: “Our RAS-targeting franchise continues to advance rapidly in the clinic, reflecting our strong operational execution and high investigator and patient enthusiasm.
“Importantly, the best-in-class potential of our pan-RAS molecular glue ERAS-0015 was underscored by ongoing partial responses at a low dose of 8 mg QD across multiple tumor types and RAS mutations, together with favorable safety and pharmacokinetics (PK) data, as of the data cutoff*.
“This clinical progress and the successful upsized public offering heighten excitement in our RAS-targeting franchise and strengthen our financial position as we further advance clinical development.
“In 2026, we expect additional Phase 1 data for ERAS-0015 in 1H 2026, as well as initial data for our pan-KRAS inhibitor ERAS-4001 in 2H 2026.
“Our focus continues to be on streamlined execution across our clinical programs, and with our recent capital infusion, we believe that we are strongly positioned to drive our RAS-targeting franchise for the benefit of patients.”
Andres Y. Maldonado, a top 9% analyst from HC Wainwright & Co. maintains ERAS with a buy rating and raises their ERAS price target from $15.00 to $20.00, on Mar 13, 2026.
Kaveri Pohlman, a top 15% analyst from Clear Street maintains ERAS with a strong buy rating and raises their ERAS price target from $11.00 to $20.00, on Mar 6, 2026.
You can dig deeper into what analysts are saying on the Erasca stock forecast page.
Metrics for Advanced ERAS Traders
Latest Insiders Trades at ERAS
Over the last year, insiders at ERAS have bought more shares than they have sold.
Ebun Garner, Chief Legal Officer of ERAS, was the latest ERAS insider to buy. They bought $136,000.00 worth of ERAS stock on Apr 1, 2026.
Research more about who owns ERAS shares here.
Can I get consistent income from ERAS stock?
No, Erasca doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Make your ERAS buy order
You have two primary options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are generally fine. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a specific price limit, use a limit order.
Click the Open button and your broker will place the order.
If you want additional info about buying stocks on eToro, watch the how to video below:
Step 6: Keep an eye on your ERAS investment
Now that you own some ERAS stock, you'll want to stay up-to-date on your new shares.
Make a watchlist to keep track of your ERAS stock.
ERAS Feed
How to Buy Stock in Erasca
To summarize, here are the 6 steps to buy Erasca stock:
- Figure out where to buy Erasca stock
- Open your brokerage account
- Fund your brokerage account
- Evaluate Erasca stock
- Make your ERAS buy order
- Keep an eye on your ERAS investment
If you are looking for a place to buy stocks, eToro is our recommended venue.
Get Started with eToro TodayIf you want to get the latest scoop on your new investment in Erasca, create your watchlist below.
Related "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.